A negative economic climate has severely impacted blue-chip stocks in the recent past, as well as stocks under $1 . Especially during Covid-19. A recent study suggests that a new strain of the disease has came, and is spreading globally, but thankfully it has milder symptoms and is being treated more effectively.
Even though it was described as mild, the financial markets have been more volatile and uncertain. Blue-chip stocks have been flat recently, yet stock under $1 have performed well. It is relatively easy to profit from penny stocks because they are unregulated.
High-volatility stocks under $1 offer a great opportunity to profit from market movements but are also risky unless you understand what they are doing and how they behave.
Making smart investment decisions begins with researching relevant stocks. Investing in stocks under $1 may yield similar returns to stocks in the Fortune 500, if you manage the metrics and fundamentals carefully.
Below are my recommendations for stocks under $1.
Infinity Pharmaceuticals Inc:
Infinity Pharmaceuticals Inc. (NASDAQ: infi) shares plummeted during Thursday’s trading session, losing -$0.06 to see the stock exchange hands at $0.99 per unit. At the moment, the company has a debt-to-equity ratio of 0.00. Following the trades, the stock’s 52-week low price has moved to $0.97 with the infi share now at $3.89 for its 52-weeks high, making it a good stock under $1.
Infinity Pharmaceuticals Inc. (NASDAQ: infi) share prices have decreased by -11.61% over the past week, but are down -50.00% in the last quarter. Going further back, the stock’s price has tanked -72.42% over the last 6 months but is down -56.00% in year-to-date trading.
Infinity Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing novel medicines for people with cancer. Its product candidate is IPI-549, an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma, which is in Phase 1/1b clinical trials for the treatment of triple-negative breast cancer, solid tumors, and ovarian cancer.
The company has strategic alliances with Intellikine, Inc. to discover, develop, and commercialize pharmaceutical products targeting the delta and/or gamma isoforms of PI3K; Verastem, Inc. to research, develop, commercialize, and manufacture duvelisib and products containing duvelisib; and PellePharm, Inc. to develop and commercialize rights to its hedgehog inhibitor program, IPI-926.
Partners:
A clinical-stage product candidate, as well as collaboration agreements with Arcus Biosciences, Inc., F. Hoffmann-La Roche Ltd., and Bristol Myers Squibb Company.
The big shareholder groups in Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) have power over the company. Institutions often own shares in more established companies, while it’s not unusual to see insiders own a fair bit of smaller companies.
With a market capitalization of US$110m, Infinity Pharmaceuticals is a small-cap stock, so it might not be well known by many institutional investors. In the chart below, we can see that institutional investors have bought into the company. We can zoom in on the different ownership groups, to learn more about Infinity Pharmaceuticals.
Institutional investors commonly compare their own returns to the returns of a commonly followed index. So they generally do consider buying larger companies that are included in the relevant benchmark index.
Sio Gene Therapies Inc:
The Sio Gene Therapies Inc. (NASDAQ:siox) went down by -0.90% in Thursday’s trading session, a fall equivalent to $0.0 from pervious market close price. The lowest point that the shares touched during the trading session was $0.63, while the peak of the day was recorded at a share price of $0.67, which is good for stock under $1.
siox finished the previous session at $0.64 according to the data provided by Barchart, while the trading volume was observed to be 0.2 million best for stocks under $1.
In terms of its performance, siox is down -75.14% over the past year, and it is down -0.41% over the last week. The stock’s price index is -29.29% lower over one month and -58.41% lower over three months. It is showing a -69.98% return in the past six months but still it makes its way for good stock under $1.
About SIOX:
Sio Gene Therapies, Inc., a clinical-stage company, focuses on developing gene therapies to radically transform the lives of patients with neurodegenerative diseases. The company develops AXO-Lenti-PD, in vivo lentiviral gene therapy, which is in Phase II clinical trials for the treatment of Parkinson’s disease; AXO-AAV-GM1.
An investigational gene therapy , which is in Phase I/II clinical trials for the treatment of GM1 gangliosidosis; and AXO-AAV-GM2, an investigational gene therapy, which is in Phase I/II clinical trials for the treatment of GM2 gangliosidosis.
It has a license agreement with Oxford BioMedica (UK) Ltd. to develop and commercialize AXO-Lenti-PD and related gene therapy products; and The University of Massachusetts Medical School to develop and commercialize gene therapy product candidates, including AXO-AAV-GM1 and AXO-AAV-GM.
The company was formerly known as Axovant Gene Therapies Ltd. and changed its name to Sio Gene Therapies, Inc. in November 2020. Sio Gene Therapies, Inc. was incorporated in 2014 and is based in New York, New York.
Quarterly Earnings:
Research and development expenses were $21.3 million for the three months ended December 31, 2021 and $6.4 million for the three months ended December 31, 2020, increasing by $14.9 million giving it a go ahead call for stock under $1. The $14.9 million increase was primarily related to:
Increased AXO-AAV-GM1 program expenses primarily related to clinical trial material manufacturing expenses for the planned enrollment of infantile patients in the high-dose cohort, as well as a $1.5 million license fee milestone due in December 2021.
Under the terms of our exclusive license agreement with the University of Massachusetts Medical School (“UMMS” and collectively, the “UMMS Agreement”);
General and administrative expenses were $4.1 million for the three months ended December 31, 2021 and $4.2 million for the three months ended December 31, 2020.
The decrease of $0.1 million was primarily related to decreases totaling $1.0 million for (i) rent, depreciation.
Overhead expenses due to the downsizing of our New York office footprint, and (ii) tax, legal, auditing. Accounting fees resulting primarily from the simplification of our corporate structure. The domestication of Sio Gene Therapies Inc. from Bermuda to Delaware that was completed in November 2020.
These decreases were partially offset by an increase of $0.7 million of stock-based compensation cost. Primarily associated with certain equity instruments of our affiliate, Roivant Sciences Ltd. (“RSL”), held by our former CEO (the “RSL Equity Instruments”), who resigned as our CEO in January 2022.
Esports Entertainment Group Inc:
With over 1.88 million Esports Entertainment Group Inc. (gmbl) shares trading Thursday and a closing price of $0.80 on the day, the dollar volume was approximately 1.88 million. The shares have shown a negative weekly performance of -35.81% and its price on 03/03/22 lost nearly -6.72%. There are 22.54M common shares owned by the public and among those 21.07M shares have been available to trade better for stock under $1.
gmbl stock lost -35.81% during the last week and fall -73.82% over the last one-month period. Shares of this company’s stock fall -82.88% throughout the last quarter. Within the last six months, the stock has decreased -90.96%, with a full-year loss of -95.66%. At the time of writing, this stock’s year-to-date (YTD) price performance is now negative at -77.32%.
Esports Entertainment Group, Inc. operates as an iGaming and entertainment company in the United States and internationally. The company operates Vie.bet, an esports focused platform; Sportnation.bet, an online sportsbook and casino; iDefix, a casino-platform; Bethard, an online sportsbook and casino; Vie.gg, an online esports wagering website. GgCircuit, a local area network center management software for managing mission critical functions. Game licensing and payments, which makes it good for stock under $1.
It also organizes professional and amateur esports events.
Quarterly earnings:
- Gross margin of 55.2% compared to 60.7% in 1Q22
- As of December 31, 2021, the Company had total cash and cash equivalents of $1.0 million
